^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PF-07062119

i
Other names: PF-07062119, PF 07062119
Associations
Trials
Company:
Pfizer
Drug class:
CD3 agonist, GUCY2C inhibitor
Related drugs:
Associations
Trials
9ms
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. (clinicaltrials.gov)
P1, N=78, Terminated, Pfizer | N=130 --> 78 | Trial completion date: Sep 2025 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Nov 2023; Study was terminated due to strategic considerations and not due to safety.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
Avastin (bevacizumab) • sasanlimab (PF-06801591) • PF-07062119
over3years
Preclinical Evaluation of Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy. (PubMed, Mol Imaging Biol)
Immune-imaging technologies for quantitative cellular measures would be a valuable biomarker in immunotherapeutic clinical development. We demonstrated a qualification of Zr-IAB22M2C PET to evaluate PD responses (mice) to a novel immunotherapeutic.
Preclinical • Journal • IO biomarker
|
CD8 (cluster of differentiation 8)
|
PF-07062119
over4years
[VIRTUAL] A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors (AACR-II 2020)
These data highlight the potential for PF-07062119 to demonstrate efficacy and improve patient outcomes in CRC and other gastrointestinal malignancies. A clinical Phase I study has been initiated in patients with CRC, gastric and esophageal adenocarcinomas (NCT04171141).
PD(L)-1 Biomarker • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS mutation • BRAF mutation
|
PF-07062119
almost5years
A Novel GUCY2C-CD3 T cell Engaging Bispecific construct (PF-07062119) for the Treatment of Gastrointestinal Cancers. (PubMed, Clin Cancer Res)
These data highlight the potential for PF-07062119 to demonstrate efficacy and improve patient outcomes in CRC and other gastrointestinal malignancies.
Journal • PD(L)-1 Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
PF-07062119